Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IDXX 
IDEXX Laboratories Inc (IDXX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: IDXX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $516.15
1 Year Target Price $516.15
| 3 | Strong Buy |
| 3 | Buy |
| 6 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.78% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 43.48B USD | Price to earnings Ratio 49.74 | 1Y Target Price 516.15 |
Price to earnings Ratio 49.74 | 1Y Target Price 516.15 | ||
Volume (30-day avg) 13 | Beta 1.55 | 52 Weeks Range 356.14 - 549.52 | Updated Date 07/10/2025 |
52 Weeks Range 356.14 - 549.52 | Updated Date 07/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 10.87 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 22.76% | Operating Margin (TTM) 31.7% |
Management Effectiveness
Return on Assets (TTM) 22.98% | Return on Equity (TTM) 59.33% |
Valuation
Trailing PE 49.74 | Forward PE 44.84 | Enterprise Value 44374694206 | Price to Sales(TTM) 11.06 |
Enterprise Value 44374694206 | Price to Sales(TTM) 11.06 | ||
Enterprise Value to Revenue 11.29 | Enterprise Value to EBITDA 34.41 | Shares Outstanding 80421904 | Shares Floating 79554165 |
Shares Outstanding 80421904 | Shares Floating 79554165 | ||
Percent Insiders 0.67 | Percent Institutions 97.51 |
Upturn AI SWOT
IDEXX Laboratories Inc
Company Overview
History and Background
IDEXX Laboratories, Inc. was founded in 1983 in Maine. Initially focused on agricultural animal diagnostics, it quickly expanded into companion animal healthcare. A significant milestone was the introduction of the SNAP ELISA test in 1991, revolutionizing in-clinic testing. It has grown through organic growth and acquisitions, establishing itself as a leader in veterinary diagnostics and software.
Core Business Areas
- Companion Animal Group (CAG): This segment focuses on diagnostics, point-of-care testing, and imaging for companion animals. It includes in-clinic diagnostic tests, reference laboratory services, and digital radiography solutions.
- Water Quality Products (Water): This segment develops and sells water quality testing products for human and animal health, including tests for detecting bacteria and contaminants in water supplies.
- Livestock, Poultry and Dairy (LPD): This segment develops and sells diagnostic tests and related products for livestock, poultry, and dairy animals, focusing on disease prevention and improved animal health.
- Software and Services: Provides practice management software, data analytics, and related services to veterinary practices.
Leadership and Structure
Jonathan Ayers (Chairman) & Jay Mazelsky (President and CEO). The company is structured into business segments, with functional departments supporting operations, R&D, and sales/marketing.
Top Products and Market Share
Key Offerings
- SNAP Tests: Rapid in-clinic diagnostic tests for various animal diseases. Market share is significant in the point-of-care testing segment, estimated to be around 40% globally for rapid tests. Competitors: Zoetis (ZTS), Heska (HSKA, now part of Zoetis).
- Reference Laboratories: IDEXX operates a global network of reference laboratories providing comprehensive diagnostic testing services. Market share is estimated at 35% globally, based on available data. Competitors: Antech Diagnostics (Mars Inc.), VCA Antech (Mars Inc.).
- VetConnect PLUS: A software platform that integrates diagnostic data and practice management tools. The platform provides real-time data insights and simplifies workflows for veterinary practices. Competitors: Covetrus (CVET), Patterson Companies (PDCO).
Market Dynamics
Industry Overview
The veterinary diagnostics market is growing due to increasing pet ownership, rising pet healthcare spending, and advancements in diagnostic technologies. The water quality testing market is also expanding due to increased regulatory scrutiny and concerns about water safety.
Positioning
IDEXX is a leading player in the veterinary diagnostics market, with a strong brand reputation, a broad product portfolio, and a global presence. It holds a strong competitive advantage through its integrated diagnostic solutions and software platforms.
Total Addressable Market (TAM)
The global animal health market is projected to reach $66 billion by 2026. IDEXX is positioned to capture a significant portion of this market, estimated around 15-20% of TAM through organic growth and expansion into new product offerings.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Broad product portfolio
- Global presence
- Integrated diagnostic solutions
- Recurring revenue model
- Significant investment in Research and Development
Weaknesses
- High valuation
- Dependence on companion animal market
- Exposure to currency fluctuations
- Competitive pressure from larger diversified companies
Opportunities
- Expansion into emerging markets
- Development of new diagnostic technologies
- Growth in pet insurance adoption
- Increasing demand for preventive care
- Growing demand for point-of-care diagnostics
Threats
- Economic downturns
- Increased competition
- Regulatory changes
- Technological obsolescence
- Consolidation of veterinary practices
Competitors and Market Share
Key Competitors
- ZTS
- ELAN.PA
- CVET
Competitive Landscape
IDEXX has an advantage due to its specialized focus on veterinary diagnostics and software, while Zoetis (ZTS) has a broader animal health portfolio. Elanco Animal Health (ELAN.PA) offers a wide range of products, but not as much of a focus in the diagnostics market.
Major Acquisitions
ezyVet
- Year: 2021
- Acquisition Price (USD millions): 212
- Strategic Rationale: Enhanced practice management software capabilities and expanded global reach in veterinary clinics.
Blueprint OpCo, Inc.
- Year: 2023
- Acquisition Price (USD millions): 167.5
- Strategic Rationale: Further enhancement of their laboratory information management systems.
Growth Trajectory and Initiatives
Historical Growth: IDEXX has experienced strong historical growth driven by organic expansion and strategic acquisitions. Revenue growth has consistently exceeded industry averages.
Future Projections: Analysts project continued revenue growth of 8-12% annually over the next 3-5 years. EPS is expected to grow at a similar rate, driven by increased profitability and share buybacks.
Recent Initiatives: Focus on expanding into international markets, developing new diagnostic tests, and enhancing its software platforms. Continued investment in R&D for innovative products and services.
Summary
IDEXX Laboratories is a strong company with a leading position in the veterinary diagnostics market. Its recurring revenue model, innovative products, and strategic acquisitions drive consistent growth. High valuation and competition pose some challenges but do not pose any risk for growth. The company is poised for continued success in the growing animal health market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Earnings Call Transcripts
- Analyst Reports (e.g., from major investment banks)
- Industry Reports (e.g., from market research firms)
- Company Website
- FactSet, Bloomberg
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may vary. Financial data is as of the latest available reporting period. Future performance is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IDEXX Laboratories Inc
Exchange NASDAQ | Headquaters Westbrook, ME, United States | ||
IPO Launch date 1991-06-21 | President, CEO & Director Mr. Jonathan J. Mazelsky | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 11000 | Website https://www.idexx.com |
Full time employees 11000 | Website https://www.idexx.com | ||
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, it offers diagnostic tests, services, and related instrumentation for manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.